Key result
Renal denervation appears safe and potentially effective for treating hypertension in patients with CKD.
Why the study?
Renal denervation is a new treatment for hypertension in patients with chronic kidney disease, but its efficacy remains debated.
Does renal denervation improve blood pressure and renal parameters in patients with chronic kidney disease and hypertension?
Meta-Analysis
Does renal denervation improve blood pressure and renal parameters in patients with chronic kidney disease and hypertension?
p-value: p=> 0.05
Renal denervation appears to be a safe and potentially effective treatment for hypertension in patients with chronic kidney disease, though high-quality RCTs are needed to confirm efficacy.
May support renal denervation for hypertension in CKD without major safety issues; leaves open confirmation of efficacy by RCTs.
BACKGROUND: Renal denervation (RDN) is a new treatment for hypertension in patients with chronic kidney disease (CKD), but its efficacy is still debated. This meta-analysis aimed to evaluate the efficacy and safety of RDN for hypertension in patients with CKD. METHODS: PubMed, Web of Science, EMBASE, and Ovid databases were searched for relevant studies published. We performed both fixed- and random-effects meta-analyses of the changes in blood pressure, estimated glomerular filtration rate (eGFR), and urinary albumin-to-creatinine ratio (UACR) after RDN. RESULTS: > 0.05), and few major complications were encountered. CONCLUSIONS: The meta-analysis showed that RDN may be effective and safe for treating CKD patients with hypertension. Well-designed randomized controlled trials of RDN are urgently needed to confirm the safety and reproducibility of RDN and to assess its impact on clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2021) conducted a meta-analysis in hypertension in patients with chronic kidney disease. Renal denervation was evaluated on changes in blood pressure, estimated glomerular filtration rate (eGFR), and urinary albumin-to-creatinine ratio (UACR) (p=> 0.05). Renal denervation may be effective and safe for treating hypertension in patients with chronic kidney disease, with few major complications encountered (P > 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: